Inquiry Basket
Loading ......
Filter By Product Search for
Cyclopentobarbital
Cyclopentobarbital Full Name
Cyclopentobarbital
Cyclopentobarbital Introduction
Cyclopentobarbital is a short-acting barbiturate that belongs to the central nervous system (CNS) depressant class, sharing a pharmacological profile with other clinically established barbiturates such as pentobarbital and phenobarbital. Although its clinical use has largely been replaced by safer sedative-hypnotic agents, Cyclopentobarbital remains an important research compound for investigating inhibitory neurotransmission, anesthetic mechanisms, and seizure control. Its primary molecular target is the GABAA receptor, a ligand-gated chloride channel responsible for maintaining neuronal inhibitory tone. Unlike benzodiazepines, barbiturates bind to a distinct allosteric site on the receptor and prolong chloride channel opening, thereby enhancing GABA-mediated inhibition and reducing neuronal excitability. This mechanism makes Cyclopentobarbital a valuable pharmacological tool for studying sedation, hypnosis, anticonvulsant activity, and anesthetic responses. Because GABAA receptor function is tightly regulated by multiple receptor subunits, including GABRA1, GABRB1, GABRB3, and GABRA6, receptor composition can significantly influence drug sensitivity, efficacy, and adverse neurological outcomes.
Beyond receptor pharmacology, growing evidence highlights the importance of pharmacogenomics in determining individual responses to barbiturates. Studies of structurally related compounds indicate that hepatic metabolism is primarily mediated by CYP450 enzymes, particularly CYP1A2, CYP2B6, and CYP3A4, while drug disposition may also be influenced by transporters such as ABCB1 and ABCG2. Genetic polymorphisms affecting these enzymes and transport proteins can alter drug clearance, systemic exposure, and toxicity risk, contributing to considerable interpatient variability. Furthermore, genes involved in neuronal plasticity and neuroinflammation, including BDNF, IL6, TNF, and APOE, have been associated with differences in therapeutic response and susceptibility to cognitive impairment during barbiturate treatment. As precision medicine continues to reshape neurological therapeutics, understanding these molecular determinants has become increasingly important for optimizing dosing strategies, minimizing adverse reactions, and improving the safety profile of GABAergic drugs in both experimental and clinical settings.
The biological pathways targeted by Cyclopentobarbital are closely linked to numerous neurological and neuropsychiatric disorders characterized by disrupted inhibitory neurotransmission. Dysfunction or pathogenic variants in GABAA receptor subunit genes, particularly GABRA1, GABRB1, and GABRB3, have been strongly associated with epilepsy, developmental and epileptic encephalopathies, autism spectrum disorders, intellectual disability, and other neurodevelopmental conditions. Enhanced GABAergic signaling produced by barbiturates remains an effective strategy for suppressing excessive neuronal firing in acute seizures and status epilepticus, while experimental studies continue to explore broader applications in anxiety, sleep disorders, anesthesia, and neuroprotection. In parallel, increasing recognition of neuroinflammatory pathways involving cytokines such as IL6 and TNF suggests that inflammatory status may also influence drug responsiveness and disease progression. Consequently, Cyclopentobarbital serves not only as a classic CNS depressant but also as a valuable research molecule for investigating GABA receptor biology, pharmacogenomic variability, and the molecular mechanisms underlying epilepsy, cognitive dysfunction, and other disorders driven by impaired inhibitory neural signaling.
Alternate Names for Cyclopentobarbital
Cyclopentobarbital
Loading ......
